iCell Gene Therapeutics to Present at Key Industry Conferences in 2026
News related to:iCell Gene Therapeutics · 2 min read
STONY BROOK, N.Y., Oct. 05, 2026 /CourierPR/ -- iCell Gene Therapeutics, a clinical-stage biopharmaceutical company developing autologous and in vivo CAR T cell therapies for autoimmune diseases and cancer, is set to make significant strides in the coming months with presentations and meetings at various industry conferences.
Jennifer Chow, CEO of iCell Gene Therapeutics, will present at the Cell & Gene Meeting on the Mesa, scheduled for October 5-7, 2026. The company's spotlight presentation is set for October 6 at 4:30 p.m. MST (7:30 p.m. ET).
In addition to the Cell & Gene Meeting on the Mesa, iCell Gene's management team will also participate in several other key industry events. They will attend the BioFuture 2026 conference in New York, NY, from October 27-28, 2026, and the Wolfe Research Healthcare Conference in the same city from November 9-10, 2026. The company's representatives will also be present at the BIO-Europe 2026 conference in Cologne, Germany, from November 9-11, 2026, and the UBS Healthcare Conference and the Jefferies Healthcare Conference, both held in London, United Kingdom, from November 16-19, 2026.
iCell Gene Therapeutics is advancing its lead program, ICG318, an armored compound CD19/BCMA CAR T, which has achieved remarkable results. The therapy has demonstrated 92% medication-free DORIS remission in SLE/lupus nephritis patients, with a mean follow-up period of nearly three years. The company is preparing for a pivotal trial of ICG318 in 2027. Furthermore, a Phase 1 investigator-initiated trial in inflammatory bowel disease is currently enrolling participants.
The company's SINIR1 in vivo platform, expected to enter clinical trials in mid-2027, combines a proprietary retroviral vector, manufactured in-house, with the company's library of armored compound CAR constructs. This innovative approach aims to provide more targeted and effective treatments for a range of diseases, including autoimmune conditions and solid tumors.
iCell Gene Therapeutics is headquartered in Stony Brook, New York, and continues to make significant progress in the field of gene therapy. The upcoming presentations and meetings will provide valuable opportunities for the company to showcase its advancements and engage with key stakeholders in the biopharmaceutical industry.